Gimv — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation.
BiotechHealthtechMedfield, US
Roger Heerman(Chief Business/Operating Officer / Co-Founder)inFrazer Morgan(Chief Development Officer / Co-Founder)inRobert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)
BoardJamil Beg(Director of the Issuer)inTom King(Director of the Issuer)
Co-investors5AM VenturesAtlas VentureRA CapitalEQT Life SciencesSixty Degree CapitalVivo Capital+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.